2019 Highlight Speakers
Alexander P. Lin, PhD
Director of the Center for Clinical Spectroscopy in the department of radiology at Brigham and Women’s Hospital
Assistant Professor of Radiology at Harvard Medical School
Masters degree in Bioengineering
Ph.D. in Biochemistry and Molecular Biophysics
Dr. Lin is a graduate of the California Institute of Technology, where he completed his Masters degree in Bioengineering and his doctoral degree in Biochemistry and Molecular Biophysics. Dr. Lin commenced at Brigham and Women’s Hospital in 2009 where his research has focused on translating magnetic resonance spectroscopy technology into clinical practice in areas.
Changning Wang
Assistant Professor at Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School
His research focus on the development and application of novel Positron emission tomography (PET) imaging probes to study disease mechanism and assist drug discovery. HE had developed several probes targeting epigenetics, neuroreceptors and kinases. One of these probes has been used in human imaging research.
Shai Gozani
President and CEO of NeuroMetrix
B.A. degree in Computer Science
M.S. degree in Electrical Engineering & Computer Science (Biomedical Engineering Focus)
Ph.D. in Neurobiology, from the University of California, Berkeley
Shai Gozani, founded NeuroMetrix, Inc. in 1996 and currently serves as Chairman of the board of directors and as our President and Chief Executive Officer. Shai has led the Company from a venture capital backed start-up, through an initial public offering on Nasdaq, through development of a successful diagnostics business, and presently into the wearable technology sector. Shai also received an M.D. from Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology at M.I.T.
Yi Zheng
(Moderator)
Instructor at Department of Radiology, Massachusetts General Hospital and Harvard Medical School.
Ph.D. degree from University of Texas of Austin.
Yi Zheng’s research focus on pre-clinical studies of pharmacological treatment for ischemic and hemorrhagic strokes. Currently he is part of a NIH Blue Print project team to develop new lipoxygenase inhibitors as a neuroprotection agent for ischemic strokes. This task team combines joint forces from two academic institutes, NIH and pharmaceutical industry.